Psyence Biomedical Says It Remains Confident That PsyLabs Is On Track To Produce GMP Certified, Nature-derived Psychedelic APIs
Psyence Biomedical Says It Remains Confident That PsyLabs Is On Track To Produce GMP Certified, Nature-derived Psychedelic APIs
Psyence生物醫藥表示，他們依然對PsyLabs能夠按計劃生產通過GMP認證的，源自自然的致幻API感到自信。
Following the successful export of its psilocybin extract to its CDMO in the UK, PsyLabs has now entered phase two of its development process.
在將其溴菌素提取物成功出口到位於英國的CDMO後，PsyLabs現在已進入其發展進程的第二階段。
The CDMO has commenced work on upscaling the purification process to validate its commercial viability, ensuring that the extraction methodology developed by PsyLabs can be efficiently scaled for larger production volumes.
CDMO已經着手提升純化過程，以驗證其商業可行性，確保PsyLabs開發的萃取方法能夠有效擴展到更大的生產規模。
This critical phase will confirm that the methods used to achieve PsyLabs' high-purity psilocybin can be replicated on a commercial scale, setting the foundation for E.U. GMP certification.
這個關鍵階段將確認用於實現PsyLabs高純度溴菌素的方法能夠在商業規模上覆制，爲歐盟GMP認證奠定基礎。
熱門討論
FOMC維持利率但不確定性高企：美股後市走向如何？
🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？
Moo Live
03/20 02:25
聯邦公開市場委員會新聞發佈會，2025年3月19日